Key Takeaways
- Q3 missed on a shipment delay, not demand: Revenue fell short by ~INR 20 crores because a key intermediate arrived late and European holidays pushed the shipment into January; the underlying order book and inquiry pipeline remain intact.
- The margin reset is structural, not cyclical: CDMO margins compressed to ~17% from 22% as the revenue mix shifted from high-margin late-phase development toward commercial supply and earlier-phase work, a pattern management expects to persist into next year.
- India is the margin recovery story: The Bavla site, once a ~40% EBITDA margin engine at INR 550 crores revenue, is now at 20-25% utilization with all regulatory hurdles cleared; management targets INR 500 crores revenue in 12-18 months and calls it the group's highest-margin site.
- ADC capabilities are deep but revenue contribution is tiny: The linker and payload Dishman supplies represent less than 1.5% of the final drug price, so even blockbuster end-sales translate to minuscule revenue; capacity expansion is underway but the payoff is years out.
- What to watch next quarter: Whether the delayed Q3 shipment converts to recognized revenue, the pace of RFP conversion for the India site, and any concrete timeline on the FDA PAI inspection at Vionnaz.
The Quarter: What Happened and Why
- Shipment delay, not demand destruction: Revenue missed expectations by ~INR 20 crores solely because a key intermediate supply was delayed and the European holiday season prevented December shipment; the material has already gone out in January.
- COGS spike was mix-driven: COGS rose to ~20% of revenue from ~15% YoY because Q3 carried more commercial supply (structurally lower margin) versus the development-heavy first half, plus good revenue from non-late-phase III molecules that carry thinner margins than phase III work.
- Employee costs included one-off severance: The INR 355 crores employee expense line embeds severance packages paid to departing employees at December-end, plus a social insurance cost provision booked this quarter.
- Finance cost inflated by refinancing charge: The INR 45.7 crores finance cost includes a ~INR 11 crore one-time expense from new syndicated facilities in Switzerland covering refinancing and credit enhancement; underlying borrowing costs are falling as SARON dropped to 0% and effective interest is now 3-3.5%.
- Nine-month trends are healthier: COGS is lower YoY on higher development revenue contribution, especially late phase III molecules; borrowing costs are declining at the Swiss entity; the quarterly noise obscures an improving trajectory.
Dalal: "The right way to look at our business would be more on a yearly basis, if not on a two-yearly basis."
CDMO: The Core Engine
- Margin compression is the new normal for now: CDMO EBITDA margin fell to ~17% from 22% because the prior year was unusually rich in late-phase molecules; management expects the same trend next year, with development revenue dominating commercial.
- New leukemia molecule commercialized: A molecule developed at the Swiss site and now supplied from there was commercialized this quarter; management calls the market opportunity "quite significant" and says it could possibly be a blockbuster drug.
- ADC pipeline is real but revenue is distant: The linker-payload Dishman supplies for an approved ADC has now received priority approval for first-line metastatic breast cancer and breakthrough therapy designation; other ADC molecules include one in phase III and a phase II candidate expected to go commercial in 12-18 months that the customer believes could be another blockbuster.
- ADC capacity expansion on track: The second round of co-investment for ADC capacity should be completed in about one and a half years.
- Celonic partnership closes the loop: The partnership lets Dishman offer an end-to-end solution covering antibodies, conjugation, payload, and linker; RFPs have already been submitted to customers with this full proposition, and small biotechs developing antibodies with Celonic are now approaching Dishman for linker-payload production.
- SPRINT initiative launched for early-stage work: A branded initiative targeting non-GMP and early-phase activities; first orders are arriving now and in the coming weeks.
- Swiss site is capacity-constrained on large-volume work: Historically focused on small niche molecules, the Swiss entity has had to turn away higher-volume business as oncology and ADC/highly potent compounds grew; this is the strategic rationale for shifting production to India.
Dalal: "Our people, they are extremely talented, the scientists that we have, and that is the reason we have been able to crack this kind of complex technologies, which people are talking about today, which we had mastered 15 years back."
India: The Margin Recovery Bet
- The Bavla site was a ~40% EBITDA margin engine at INR 550 crores revenue in FY2020, then EDQM observations in March 2020 crushed performance for 4-5 years; all regulatory issues are now resolved, including successful FDA, Japanese PMDA, and EDQM clearances.
- Utilization is only 20-25% today, meaning the operating leverage runway is substantial; management calls this the highest-margin site in the entire group.
- Revenue ramp targets are specific: INR 500 crores in 12-18 months, then INR 800 crores in 3-5 years; Q4 FY26 revenue should be higher than Q3, with bigger growth in FY27, and the site should exit FY26 near INR 250 crores.
- RFP conversion is the gating item: Management expects fair visibility on RFP conversion in the next six months; some RFPs have already converted, some are in process, and manufacturing takes 4-5 months post-conversion; partial contribution hits FY27, with the major part in FY28.
- Customer visits are happening: Four clients visited in the last month, with more expected next quarter; a Japanese customer has received a quote for final API for both Japanese and Chinese markets, with final confirmation expected in April or May.
- Production shift strategy is explicit: Management wants to move more production into India and fill the Shanghai site quickly; a potential EU-India free trade agreement would accelerate this by reducing tariffs on fine chemicals.
Dalal: "This is the site which is going to give us the highest margins as far as the entire group is concerned."
Marketable Molecules: The Quiet Improver
- Q3 margin reached 7.2%, up on higher cholesterol sales versus the prior quarter; nine-month margins improved 920 bps to 17.5% from 8.3%, driven by vitamin D analogs and cholesterol.
- Vitamin D analogs are the high-margin star: Management calls this branch of the portfolio "very satisfying" on margin.
- Cholesterol cost reduction continues: New sources opened for the main starting material at the Veenendaal facility, specifically on wool grease.
- Stated margin target: First get to 20%, then take it up to 25% for the segment.
Dalal: "As you look into the future for this particular segment, and more specifically cholesterol and vitamin D analogs, we would keep on seeing the margin improvements, where our target is to first get to the 20% margin and then take it up to 25%."
Capacity, Sites, and the Global Footprint
| Site | Utilization | Commentary |
|---|---|---|
| Switzerland | 75% | Capacity-constrained on large-volume work; focus is niche, oncology, ADC/HPAPI. |
| France | 20% | Just started last year; delayed truck substance supply pushed revenue into FY27; expected breakeven at EBITDA level in FY27 with both lines running, revenue near EUR 1.8 crore. |
| Netherlands | 60% | Wool grease sourcing improvements underway for cholesterol production. |
| Manchester | 75% | No specific constraints flagged. |
| Shanghai | 50% | Received local FDA certification; new salesperson hired; target to reach ~75% utilization. |
| India (Bavla) | 20-25% | Highest-margin site in the group; target 2.5x utilization increase in three years. |
- No capacity constraints for commercial manufacturing exist anywhere in the network today.
- French subsidiary delayed, not derailed: Revenue is lower than expected solely because a truck substance supplier delayed delivery; that material now arrives at end of Q4, pushing the associated revenue into FY27; the site should still reach EBITDA breakeven next year.
- Shanghai turning a corner: Local FDA certification received, a dedicated salesperson hired to target the pharmaceutical market, and utilization expected to rise from 50% to ~75%.
- Asset base is optically distorted: Multi-year rupee depreciation against foreign currencies inflates the fixed asset base by nearly INR 1,000 crores; significant goodwill on the balance sheet is entirely non-cash.
Balance Sheet & Capital Allocation
- India debt reduction is a stated priority: Management wants to make India debt zero, funded by internal accruals over the next three years; a fundraise is possible but only at the right valuation.
- Finance costs should decline: Underlying Swiss borrowing costs are falling (SARON at 0%, effective rate 3-3.5%); the Q3 spike was a one-time refinancing charge of ~INR 11 crores.
- Depreciation run rate is stable: No material change expected in the depreciation and amortization trajectory going forward.
- Co-investment with Japanese customer progressing: Detailed engineering and planning underway; preliminary work started; construction will expand capabilities at Aarau and Neuland facilities in Switzerland.
Dalal: "Ideally speaking, we would want to make the India debt zero."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Q4 revenue recovery | Revenue higher by the delayed ~INR 20 crores than previously expected | Q4 FY26 |
| Full-year FY26 growth | Growth rate "much higher" than the 4.3% reported for 9M, more or less in line with prior guidance | FY26 exit |
| Full-year FY26 EBITDA margin | 19.5% to 20% (target still stands) | FY26 exit |
| India revenue | INR 500 crores | 12-18 months |
| India revenue | INR 800 crores | 3-5 years |
| India utilization | 2.5x current production capacity utilization | 3 years |
| Consolidated EBITDA margin | 25-26% (pre-March 2020 level) | 2 years |
| Consolidated EBITDA margin | 30% | By end of 2030 |
| Marketable Molecules margin | 20%, then 25% | No date (target stated) |
| French subsidiary | EBITDA breakeven with both manufacturing lines | FY27 |
| French subsidiary revenue | ~EUR 1.8 crore | FY27 |
| Shanghai utilization | ~75% (from current 50%) | No date (target stated) |
| Swiss development revenue | Double from current level | 5 years |
| ADC capacity expansion (second co-investment) | Completed | ~1.5 years |
| India debt | Zero | 3 years |
| Japanese customer visibility | Fair revenue visibility from existing co-investment | At least 3 years |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹720 cr, +5.5% YoY; expected ₹20 cr higher but delayed shipment pushed to January |
| EBITDA | ₹113 cr, margin of 15.7% |
| EBITDA margin (9M FY26) | 19.4%, vs 15.9% in 9M FY25; full-year FY26 target of 19.5%–20% |
| Profit after tax | Negative ₹12.97 cr |
| Profit before tax (9M FY26) | ₹58.76 cr |
| Profit after tax (9M FY26) | ₹75.7 cr, after accounting for deferred tax asset largely from the French facility |
| COGS | ~20% of revenue, vs ~15% in Q3 FY25, driven by higher commercial supply mix |
| Employee expenses | ₹355 cr, vs ₹332 cr in Q3 FY25; includes severance and social insurance provisions |
| Finance cost | ₹45.7 cr, including a one-time expense of ~₹11 cr from refinancing and credit facility enhancement in Switzerland |
| CDMO segment revenue | ₹630 cr, +6.7% YoY; 9M FY26 at ₹1,750 cr vs ₹1,723 cr in 9M FY25 |
| CDMO segment EBITDA margin | ~17%, vs 22% in Q3 FY25; 9M FY26 at 19.7% vs 17.2%, up ~250 bps |
| Marketable Molecules segment revenue | ₹90 cr, flattish YoY; 9M FY26 at ₹330 cr, +21.5% YoY |
| Marketable Molecules segment EBITDA margin | 7.2%; 9M FY26 at 17.5% vs 8.3%, up 920 bps |
| India (Bavla) site revenue (9M FY26) | ~₹150 cr; FY26 guidance of ₹250–₹290 cr |
| India site RFP pipeline | ₹1,200 cr worth of RFPs given out; 30%–35% expected conversion |
| India site revenue target | ₹500 cr in next 12–18 months, then ₹800 cr in 3–5 years |
| French subsidiary revenue (9M FY26) | €7 mn; full-year FY26 expected at €9.5–€10 mn; FY27 target ~€1.8 cr (likely €18 mn based on context) |
| Swiss site capacity utilization | ~75% |
| India site capacity utilization | ~20%–25% |
| French site capacity utilization | ~20% |
| Net debt | ~CHF 15 crore |
| India debt | ~₹750 cr; target to reduce to zero over next 3 years via operational cash flows |
| ADC linker-payload supply (FY25) | CHF 2.2 cr; FY26 expected ~CHF 3 cr; FY27 expected ~CHF 4 cr |
| Second co-investment with Japanese customer | CHF 2.5 cr, expected to contribute ~CHF 3 cr of incremental revenue |